BioCryst Pharmaceuticals GAAP EPS of -$2.98 misses by $3.03, revenue of $156.4M beats by $5.28M
Source: SeekingAlpha
2026-05-06 07:05:53 ET
More on BioCryst Pharmaceuticals
- BioCryst: The Buyout Rumor Is Noise, The Franchise Is Real
- BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript
- BioCryst Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation
- BioCryst Pharmaceuticals Q1 2026 Earnings Preview
- BioCryst gains amid takeover speculation
Read the full article on Seeking Alpha
For further details see:
BioCryst Pharmaceuticals GAAP EPS of -$2.98 misses by $3.03, revenue of $156.4M beats by $5.28M
BioCryst Pharmaceuticals Inc.
NASDAQ: BCRX
BCRX Trading
0.12% G/L:
$8.495 Last:
820,015 Volume:
$8.50 Open:
BCRX Latest News
May 27, 2026 07:00:00 am
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
May 13, 2026 07:00:00 am
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
May 06, 2026 07:00:00 am
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
BCRX Stock Data
$1,391,931,498
199,991,369
0.01%
88
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
